Freeport, Bahamas, The, May 25, 2012 --(PR.com
)-- Okyanos Heart Institute (http://www.okyanos.com/), which brings a new standard of care and a better quality of life to patients with “no-option” coronary artery disease (CAD) via cardiac stem cell therapy, has announced that Erika Mangrum will serve as the senior vice president of marketing. In this role, Mangrum will manage patient and physician communication, direct educational seminars and act as the facility’s media liaison in an effort to expand awareness of the innovative treatment opportunities that are available through adult stem cell therapy for patients fighting coronary artery disease.
Mangrum earned a Bachelor of Arts and a Master of Business Administration from the University of North Carolina at Chapel Hill before attending the University of San Francisco, where she earned a master’s in digital marketing. As a well-known and highly respected healthcare advocate, Mangrum previously worked with Laser Spine Institute from 2009 to 2011 as the vice president and executive director of an outpatient and clinical facility before being promoted to serve as the organization’s senior vice president of marketing. In addition, Mangrum served as a board level consultant to public and private healthcare companies internationally from 2006 until 2009 for marketing, sales and business development specializing in medical devices and healthcare products. As a faculty member with the University of California at Irvine from 2005 until 2010, Mangrum taught marketing and branding, and served on the department’s faculty advisory board. Mangrum, with her wide-ranging expertise in healthcare education, management, marketing and technology, has been interviewed by such publications as The Wall Street Journal, USA Today, Fortune Magazine, Health Magazine and Health. Additionally, as an expert in her field, she has been featured on several television networks including MSNBC, CNN, The WB, ABC, NBC and CBS. Previously, Mangrum also established and served from 1999 until 2008 as CEO of a chain of medical spas that made the Inc 5000 list of Fastest Growing Private Companies in the United States and was named the Top Medical Spa Chain in the United States by Day Spa Magazine.
“I am very excited for Erika to join Okyanos Heart Institute as the senior vice president of marketing,” said Matthew Feshbach, co-founder and CEO of Okyanos Heart Institute. “Erika’s education, experience and passion for healthcare and marketing will assist Okyanos Heart Institute as we move forward in improving the lives of individuals living with chronic coronary artery disease through the advanced treatment option of cardiac stem cell therapy.”
“I am confident in Erika’s commitment to connecting physician and patient communities as Okyanos Heart Institute continues to focus on improving the lives of those struggling day-to-day with coronary artery disease,” said Howard T. Walpole Jr., M.D., MBA, FACC, FACAI, FSCAI and chief medical officer for Okyanos Heart Institute. “As the SVP of marketing, Erika will help to foster the continued growth and development of Okyanos Heart Institute and raise awareness about the benefits of adult stem cell therapy through hosting educational seminars, communicating with the media, and managing patient and physician communication.”
New Media Content:
Okyanos LinkedIn page:
Okyanos Facebook page:
Okyanos Twitter page:
About Okyanos Heart Institute:
Based in Freeport, The Bahamas, the Okyanos Heart Institute is a Center of Excellence (CoE) adhering to U.S. surgical center standards and led by Chief Medical Officer Howard Walpole Jr., M.D., MBA, FACC, FACAI, FSCAI, a leader of the American College of Cardiology for many years. The mission of Okyanos Heart Institute is to bring a new standard of care and a better quality of life to patients with “no-option” coronary artery disease via cardiac adult stem cell therapy. The Greek god of rivers, “Okyanos” symbolizes the primary mechanism of action that these adult stem cells have on ischemic (lack of blood flow) heart tissue, the result of the plaque deposits in the coronary arteries. The stem cells, derived from a person’s adipose (fat) tissue, create new blood vessels, a process known as angiogenesis. These cells facilitate blood flow in the heart and intake and use of oxygen, as measured by a rigorous clinical trial known as the PRECISE trial, as well as cardiac cell therapy trials at leading research institutions. For more information, visit http://www.okyanos.com/.
MMI Public Relations